Skip to main content

Table 3 Multivariate Cox regression model for exploring the association between FT and clinical outcomes in patients with PD

From: Facial tremor in patients with Parkinson’s disease: prevalence, determinants and impacts on disease progression

  Model 1 Model 2
HR (95%CI) P-value HR (95%CI) P-value
Presence of FT at baseline
 Time to death 1.65 (0.87–3.12) 0.122 1.50 (0.78–2.90) 0.230
 Time to UPDRS-III 11-point increase 1.23 (0.75–2.01) 0.421 1.21 (0.73–2.00) 0.460
 Time to conversion to H&Y stage ≥3 0.95 (0.52–1.74) 0.876 0.93 (0.51–1.72) 0.822
 Time to dyskinesia 0.64 (0.25–1.61) 0.340 0.57 (0.23–1.45) 0.241
 Time to MoCA 3-point decrease 0.97 (0.57–1.64) 0.903 0.97 (0.57–1.65) 0.907
FT as initial symptom
 Time to death 2.46 (0.90–6.76) 0.080 2.56 (0.91–7.23) 0.075
 Time to UPDRS-III 11-point increase 0.91 (0.33–2.52) 0.861 0.86 (0.31–2.42) 0.777
 Time to conversion to H&Y stage ≥3 0.47 (0.11–1.96) 0.300 0.49 (0.12–2.06) 0.332
 Time to dyskinesia 1.07 (0.25–4.47) 0.931 1.09 (0.26–4.63) 0.906
 Time to MoCA 3-point decrease 0.54 (0.17–1.74) 0.301 0.50 (1.16–1.63) 0.253
  1. FT Facial tremor, PD Parkinson’s disease, UPDRS Unified PD Rating Scale, MoCA Montreal Cognitive Assessment
  2. Model 1, adjusted for sex, age, and age at onset
  3. Model 2, adjusted for sex, age, age at onset, BMI, LEDD, UPDRS III score, MoCA score, and NMSS score